690 Share Price Performance
HK$0.13
0.05 (69.74%)
Price HK$0.13
Share PriceHK$0.13
Uni-Bio Science Group (HKG:690) Seems To Use Debt Quite Sensibly
Oct 13
Uni-Bio Science Group Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
690 Community Narratives
There are no narratives available yet.
Recent 690 News & Updates
Uni-Bio Science Group's (HKG:690) Weak Earnings May Only Reveal A Part Of The Whole Picture
Sep 04Optimistic Investors Push Uni-Bio Science Group Limited (HKG:690) Shares Up 33% But Growth Is Lacking
Aug 18There's No Escaping Uni-Bio Science Group Limited's (HKG:690) Muted Earnings Despite A 32% Share Price Rise
Jul 03Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?
Jun 12The CEO Of Uni-Bio Science Group Limited (HKG:690) Might See A Pay Rise On The Horizon
May 19Uni-Bio Science Group Limited's (HKG:690) Price Is Right But Growth Is Lacking After Shares Rocket 26%
May 07Uni-Bio Science Group Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.015
- Gross Margin
- 82.19%
- Net Profit Margin
- 15.49%
- Debt/Equity Ratio
- 26.0%
Uni-Bio Science Group Limited Competitors
Snowflake Analysis
About 690
- Founded
- 2001
- Employees
- 504
- CEO
- WebsiteView website
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; and Boshutai, an oral medication for the treatment of diabetes. It also develops prescription drugs, such as UOS003(oral PTH) for the treatment of osteoporosis; Uni-GLP-1, a non-insulin treatment candidate that stimulates the incretin pathway for the treatment of type 2 diabetes and obesity; and pre-clinical stage biopharmaceutical products for wound care and ophthalmology. In addition, the company offers contract manufacture organization services. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Hong Kong Market Performance
- 7 Days: -1.5%
- 3 Months: 4.6%
- 1 Year: 26.1%
- Year to Date: 30.9%
Over the last 7 days, the market has dropped 1.5%, driven by losses in the Communication Services and Information Technology sectors of 3.2% and 8.0%, respectively. In contrast to the last week, the market is actually up 26% over the past year. Earnings are forecast to grow by 13% annually. Market details ›